![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.
Lead Product(s): Lunresertib,Camonsertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Repare Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 12, 2024
Details:
The partnership aims to impact the care of patients with late-stage colorectal cancer undergoing surgery in a Phase II trial assessing QBECO SSI in reducing post-operative immune suppression.
Lead Product(s): QBECO SSI
Therapeutic Area: Oncology Product Name: QBECO SSI
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Qu Biologics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 06, 2024
Details:
The partnership aims to develop Foundation Medicine’s FoundationOne®CDx, as a companion diagnostic for PMV’s PC14586 (rezatapopt), a first-in-class therapy for solid tumors with TP53 Y220C mutation.
Lead Product(s): Rezatapopt,Pembrolizumab
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: PMV Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2024
Details:
The collaboration aims for the development and regulatory approval of Foundation Medicine’s FoundationOne®CDx and FoundationOne®Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: AB-106
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AnHeart Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2023
Details:
Braftovi (Encorafenib) Is An Oral Small Molecule Braf Kinase Inhibitor And Combination With Cetuximab Used for Patients With Patients With Braf V600E Alterations In Metastatic Colorectal Cancer.
Lead Product(s): Encorafenib,Cetuximab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
The Partnership will focus on developing FoundationOne®CDx as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828, an investigational, oral, small molecule MDM2-p53 antagonist.
Lead Product(s): BI 907828
Therapeutic Area: Oncology Product Name: BI 907828
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2023
Details:
Initial goal of collaboration is to develop FoundationOne® liquid CDx as a companion diagnostic for Bavdegalutamide (ARV-110), Arvinas’ investigational Androgen receptor-targeting PROTAC® protein degrader.
Lead Product(s): Bavdegalutamide
Therapeutic Area: Oncology Product Name: ARV-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Arvinas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2022